CDXC: chromadex.com Market Price to Net Income Ratio

ChromaDex - graphic logo of issuer CDXC

ChromaDex Corporation (CDXC) is developing a biochemical environment for cell regeneration, leveraging proprietary NAD+ developments and the Tru Niagen brand to retain B2B partners. This price chart featuring the 71.40 metric complements data on the optimization of global digital sales and warehousing capacities. Business prospects rely on expanding demand for longevity components, which opens new distribution channels for raw materials.

ChromaDex Corp. (CDXC) - P/E Multiple from 07/04/2022 to 03/19/2025

Comprehensive metric breakdowns and analytics for chromadex.com (CDXC)

- market price and analyst price targets:
- market capitalization information:
Summary company analysis:ChromaDex Corp. - CDXC
Flagship merchandise of ChromaDex Corporation

Fundamental asset selection is based on comparing a business's market value with its actual profitability. This indicator measures the ratio of market capitalization to net income, reflecting the premium for future growth. For ChromaDex Corporation (CDXC), stable dietary supplement sales create a predictable cash flow, reducing investment risks. By analyzing the company's P/E ratio, an investor determines the degree of asset overvaluation. A downward trend in the curve signals a favorable entry point.